<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668237</url>
  </required_header>
  <id_info>
    <org_study_id>1508188</org_study_id>
    <secondary_id>16-367</secondary_id>
    <secondary_id>916352</secondary_id>
    <secondary_id>2016-A00483-48</secondary_id>
    <nct_id>NCT02668237</nct_id>
  </id_info>
  <brief_title>Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP</brief_title>
  <acronym>OptiPAC</acronym>
  <official_title>Impact on Anti-infectious Treatments of the Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Community-acquired Pneumonia of Children at Pediatric Emergencies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Community-Acquired Pneumonia (CAP) of children are a recurrent pathology with multiple
      severity scores. The etiology is never really identified, and the initial treatment is
      always based on probabilistic antibiotics, in the case of an bacterial infection, and by the
      way, potentially severe.

      Molecular tests (&quot;multiplex&quot;) allow the simultaneous detection of a huge number of
      pathogenic agents, virus and bacteria, are now available.

      This project is based on a new strategy of diagnostic, using a multiplex PCR with quick
      results, coupled to an antigenic urinary test to allow a complete, quick, etiologic
      diagnostic as soon as children are supported in emergency.

      Children are randomized in two groups during inclusions : quick diagnostic strategy versus
      usual practice. Analyse will be centralized on anti-infectious treatment optimization, with
      the aim to better treat patients, minimize the costs, and decrease selection pressure of
      multi-resistant bacteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-Acquired Pneumonia (CAP) of children are a recurrent pathology with multiple
      severity scores. Almost two out of three cases identified at emergency are treated in
      ambulatory because patients present a reassuring clinical state. The etiology is never
      really identified, and the initial treatment is always based on probabilistic antibiotics
      re-evaluated at H48, in the case of an bacterial infection, and by the way, potentially
      severe. This old conception is opposed to the new discoveries, more particularly in
      pediatric units where strictly viral pneumonia are more important than predicted (at least
      30 to 50%) that leads to an hyper prescription of antibiotics, useless.

      Molecular tests (&quot;multiplex&quot;) allow the simultaneous detection of a huge number of
      pathogenic agents, virus and bacteria, are now available.

      Aware of the non specificity of the clinical data to guide the diagnostic, this project is
      based on a new strategy of diagnostic, using a multiplex PCR with quick results (less than 2
      hours, for 20 pathogens, including 17 viruses) coupled to an antigenic urinary test to allow
      a complete, quick, etiologic diagnostic as soon as children are supported in emergency.

      Children are randomized in two groups during inclusions : quick diagnostic strategy versus
      usual practice. Analyse will be centralized on anti-infectious treatment optimization
      (antibiotics and antiviruses), with the aim to better treat patients, minimize the costs,
      and decrease selection pressure of multi-resistant bacteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appropriate prescription of an anti-infection treatment.</measure>
    <time_frame>Day 1</time_frame>
    <description>Measure the impact on the therapeutic support of the creation of a quick, diagnostic, etiologic test of Community-Acquired Pneumonia of children (less than 3 months), supported in pediatric emergency versus usual practice. The main criterion will be the appropriate prescription of an anti-infection treatment, taking into account the microbiological results obtained a posteriori and clinical evolution. The primary outcome will be measured directly in the patients source folders.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Community-Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The children will benefit from the usual care : an antibiotic prevention treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OptiPAC</intervention_name>
    <description>Molecular and urinary tests.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Antibiotics for prevention.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In emergency for a Community-Acquired Pneumonia (according to the international rules
             based on an hyperthermia &gt; 38,5°C associated to a radiological opacity)

          -  Informed Consent

          -  Possibility to take samples

        Exclusion Criteria:

          -  Nosocomial pneumonia

          -  Pleuropneumopathy

          -  Pneumonia occurring in immunosuppressed and transplanted

          -  Patient with proven allergy to antibiotics

          -  Inability to perform certain microbiological samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CANTAIS Aymeric, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CANTAIS Aymeric, MD</last_name>
    <phone>(0)4 77 82 92 54</phone>
    <phone_ext>+33</phone_ext>
    <email>aymeric.cantais@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AKROUR Madjid, CRA</last_name>
    <email>madjid.akrour@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Marseille</name>
      <address>
        <city>Marseille</city>
        <state>La Timone</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BREMOND Valérie, MD</last_name>
    </contact>
    <investigator>
      <last_name>BREMOND Valérie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GREMMO-FEGER Gisèle, MD</last_name>
    </contact>
    <investigator>
      <last_name>GREMMO-FEGER Gisèle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EKCART Philippe, MD</last_name>
    </contact>
    <investigator>
      <last_name>EKCART Philippe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LABBE André, MD</last_name>
    </contact>
    <investigator>
      <last_name>LABBE André, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FAISANT Anne, MD</last_name>
      <phone>0476767575</phone>
    </contact>
    <investigator>
      <last_name>FAISANT Anne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DIGEON Béatrice, MD</last_name>
    </contact>
    <investigator>
      <last_name>DIGEON Béatrice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>04 77 82 92 54</phone>
    </contact>
    <investigator>
      <last_name>CANTAIS Aymeric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EYER Didier, MD</last_name>
    </contact>
    <investigator>
      <last_name>EYER Didier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CLAUDET Isabelle, MD</last_name>
      <phone>0561778233</phone>
    </contact>
    <investigator>
      <last_name>CLAUDET Isabelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>January 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
